2010•Value in HealthOpen access

PSS10 COST PER RESPONDER OF USTEKINUMAB VERSUS ETANERCEPT IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS: ANALYSIS FROM THE ACCEPT TRIAL

SR Feldman, Matthias Augustin, Susan Martin, Philippe Szapary, Brad Schenkel

Open full text 0 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Ustekinumab, Etanercept, Plaque psoriasis, Medicine, Dermatology, Psoriasis, Internal medicine, Adalimumab

Back to paper search Browse research topics Original source

PSS10 COST PER RESPONDER OF USTEKINUMAB VERSUS ETANERCEPT IN PATIENTS WITH MODERATE-TO-SEVERE PLAQUE PSORIASIS: ANALYSIS FROM THE ACCEPT TRIAL — Research Paper | ScholarLens